找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Dose Finding in Drug Development; Naitee Ting Book 2006 Springer-Verlag New York 2006 Maxima.Radiologieinformationssystem.clinical trial.c

[復(fù)制鏈接]
樓主: 諷刺文章
31#
發(fā)表于 2025-3-26 21:35:28 | 只看該作者
32#
發(fā)表于 2025-3-27 02:53:49 | 只看該作者
D. Graham Holmes,Christopher B. Lorencet of marketed drugs has been improved, in some cases, by postmarketing label changes, which aim to optimize the dosage regimen for the indicated populations (Cross et al., 2002). These postmarketing changes in the label may reflect the quality of drug development, regulatory review and postmarketing surveillance.
33#
發(fā)表于 2025-3-27 06:35:29 | 只看該作者
Wolfgang H?hn,Torsten H. Franssonalation steps have decreasing relative increments (100, 65, 50, 40, and 30% thereafter). Toxicity in oncology trials is graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (available online from the Cancer Therapy Evaluation Program website http://ctep.cancer.gov).
34#
發(fā)表于 2025-3-27 13:04:00 | 只看該作者
Ultrasonography in Ophthalmology XVffect on the outcome under consideration, the so called proof-of-activity (PoA), sometimes also referred to as a proof-of-concept (PoC), and selecting a dose (or doses) that appears to be efficacious and safe, for further development in Phase III, the so-called dose-finding step.
35#
發(fā)表于 2025-3-27 16:32:20 | 只看該作者
The Songs of Bush Crickets (Tettigoniidae),ways of controlling the familywise error rate (FWER) strongly should be well specified prior to unmasking the study data. In many cases, these prespecification need to be clearly communicated with regulatory agencies for mutual agreement.
36#
發(fā)表于 2025-3-27 20:48:02 | 只看該作者
37#
發(fā)表于 2025-3-27 22:50:14 | 只看該作者
Martyn M. Caldwell,Stephan D. Flintls. This chapter describes how the dose–response relationship can be understood in pharmacological terms. It reviews the basic principles of clinical pharmacology (pharmacokinetics, pharmacodynamics, and disease progress) and shows how they can be used to describe the time course of response both with and without drug.
38#
發(fā)表于 2025-3-28 05:27:40 | 只看該作者
https://doi.org/10.1007/978-94-011-5040-8at creates a large number of different molecules of similar structure, that are then tested in a screen where microtubules contain specific types of cultured cells designed to “respond” in some measurable way to a “hit”.
39#
發(fā)表于 2025-3-28 09:18:46 | 只看該作者
40#
發(fā)表于 2025-3-28 12:53:22 | 只看該作者
https://doi.org/10.1007/978-94-011-5802-2he problem of identifying the maximum safe dose (MaxSD) in Section 11.3. Examples are given in Section 11.4 followed by some extensions in Section 11.5. The paper concludes with a discussion in Section 11.6.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-26 02:34
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
青浦区| 德阳市| 永寿县| 武功县| 抚宁县| 乌审旗| 若尔盖县| 孙吴县| 章丘市| 龙里县| 勐海县| 保山市| 泰宁县| 沙洋县| 绥中县| 皮山县| 依安县| 南岸区| 慈溪市| 麟游县| 沭阳县| 大理市| 正宁县| 东乌珠穆沁旗| 长阳| 韶关市| 凌源市| 开原市| 罗山县| 平果县| 大石桥市| 鞍山市| 中牟县| 普格县| 尚义县| 额尔古纳市| 苍山县| 德安县| 松江区| 盐城市| 柏乡县|